Search Results for "Sjogren A Belimumab"

19:56 EDT 23rd October 2016 | BioPortfolio

Matching Channels


Matching News

Sjogren's Syndrome Foundation: Rheumatology Clinical Practice Guidelines Published

BETHESDA, MD--(Marketwired - Jul 22, 2016) - As we prepare to celebrate World Sjogren's Day on July 23 rd, the SSF is excited Read more...

New Guidance on Managing Sjogren's Rheumatologic Problems

Sjogren's Syndrome Foundation experts developed new guidelines on rheumatologic manifestations of the disease including fatigue, inflammatory musculoskeletal pain, and use of biologicals. Medscape M...

Diquafosol Sodium in Dry-Eye Patients With Sjogren Syndrome

How does diquafosol sodium compare with artificial tears in terms of increasing aqueous tear volume in Sjogren's syndrome-associated dry eye? Eye

Is Salivary Gland US a Useful Tool in Sjogren's Syndrome?

What role, if any, should major salivary gland ultrasonography have in the diagnosis and management of Sjogren's syndrome? Rheumatology

New study links cathepsin S protein to tear secretion in Sjogren's syndrome patients

The autoimmune disorder Sjogren's syndrome is often overlooked or misdiagnosed because the symptoms are similar to other conditions. Its characteristic symptoms are dry eyes and dry mouth, and reduced...

GSK announces regulatory submissions for subcutaneous formulation of Benlysta® (belimumab) for patients with systemic lupus disease

It has filed regulatory submissions in the US and Europe for Benlysta® (belimumab) for approval.

Biomarkers Related to Disease Activity in Sjogren's Syndrome

The authors have identified serum biomarkers that may play a key role in evaluating disease activity in primary Sjogren's syndrome. Arthritis Research & Therapy

Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus

Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that Benlysta™ (belimumab, formerly LymphoStat-B®) met the primary endpoint in BLISS-52, the first o...

Matching PubMed Articles

Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.

Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody, appeared effective in Sjögren's syndrome (SS) in the phase II open-label 52-week BELISS study. Herein, the follow-up after the en...

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus

To study self-administration and pharmacokinetics (PK) of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE).

Secondary Sjogren's Syndrome in 83 Patients With Rheumatoid Arthritis.

Sjogren syndrome (SS) can occur alone, primary Sjogren syndrome, or in association with other rheumatic diseases, secondary Sjogren syndrome (sSS), such as Rheumatoid arthritis (RA). The occurrence of...

Rituximab-refractory lupus nephritis successfully treated with belimumab.


A rare presentation of Sjogren's syndrome.

Search Whole site using Google

Quick Search
Advertisement Advertisement